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Abstract: Hexadecyloxypropyl-cidofovir (HDP-CDV) is a novel ether lipid conjugate   
of (S)-1-(3-hydroxy-2-phosphonoylmethoxypropyl)-cytosine (CDV) which exhibits a 
remarkable increase in antiviral activity against orthopoxviruses compared with CDV. In 
contrast to CDV, HDP-CDV is orally active and lacks the nephrotoxicity of CDV itself. 
Increased oral bioavailability and increased cellular uptake is facilitated by the lipid 
portion of the molecule which is responsible for the improved activity profile. The lipid 
portion of HDP-CDV is cleaved in the cell, releasing CDV which is converted to CDV 
diphosphate, the active metabolite. HDP-CDV is a highly effective agent against a variety 
of orthopoxvirus infections in animal models of disease including vaccinia, cowpox, 
rabbitpox and ectromelia. Its activity was recently demonstrated in a case of human 
disseminated vaccinia infection after it was added to a multiple drug regimen. In addition 
to the activity against orthopoxviruses, HDP-CDV (CMX001) is active against all double 
stranded DNA viruses including CMV, HSV-1, HSV-2, EBV, adenovirus, BK virus, orf, 
JC, and papilloma viruses, and is under clinical evaluation as a treatment for human 
infections with these agents. 
Keywords: antiviral drugs; Cidofovir; HPMPA; acyclic nucleoside phosphonates; 
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1. Introduction 
Smallpox was a major cause of mortality worldwide until it was eliminated by the WHO 
vaccination program in the late 1970s [1]. It was a disease easily transmitted by aerosol which   
caused 30% mortality and disfiguring skin lesions in survivors. Vaccination for smallpox was 
discontinued thereafter and the world population has become vulnerable again to the disease because 
of minimal herd immunity. Several years ago concern arose that smallpox could be used as a 
bioweapon by hostile groups or terrorists [2,3]. In addition, genetically modified strains of poxviruses 
were shown to be lethal to animals even though they had been preimmunized by vaccination [4]. 
Although vaccination is still considered as the primary approach to a potential recurrence of smallpox, 
many individuals are now immunosupressed because of HIV infections, cancer chemotherapy and 
organ transplantation. Immunosuppressed persons would not be good candidates for vaccination [5] 
and alternative therapies are needed. A screening effort was undertaken to find agents which inhibited 
the replication of poxviruses and could be developed as therapeutics.  
2. Cidofovir Identified as an Effective Inhibitor of Poxviruses 
(S)-1-(3-hydroxy-2-phosphono-methoxypropyl)adenine (HPMPA) and (S)-1-(3-hydroxy-2-
phosphonomethoxypropyl)-cytosine (HPMPC, cidofovir) are acyclic nucleoside phosphonate antivirals 
first described by Holy and De Clercq [6,7]. Both HPMPA and HPMPC were shown to have antiviral 
activity in the vaccinia virus mouse tail lesion model [7,8]. HPMPC (cidofovir, CDV) was shown to be 
active in lethal aerosol or intranasal cowpox infections [9,10] when given by parenteral injection. CDV 
was also active when given as an aerosol in cowpox-infected mice [11]. However, CDV given 
intravenously has substantial nephrotoxicity which limits its dose to 5 mg/kg/week. In a smallpox 
outbreak, it would not be possible to use an intravenous drug with significant nephrotoxicity widely. 
An oral drug with less toxicity which could be delivered from a stockpile and self administered would 
be much more desirable for emergency use.  
3. Enhancing the Oral Activity of Antiviral Nucleosides: Early Development of the 
Alkoxyglycerol Esterification Approach 
Our early approach to antiviral drug design was to attempt to enhance cellular drug uptake by disguising 
antiviral nucleosides as diacylphosphatidylglycerol nucleoside analogs. When liposomal preparations 
containing phosphatidyl nucleoside conjugates such as 1,2-dipalmitoylphosphatidyl-2′,3′-dideoxyguanosine 
(DPP-ddG) were prepared and evaluated by intraperitoneal administration to woodchucks infected with 
woodchuck hepatitis virus, a significant antiviral effect was observed while an equimolar dose of ddG 
itself had little effect [12]. While this study clearly demonstrated the utility of a liposome 
phosphatidyl-linked antiviral nucleoside to target a liver infection, parenteral administration was 
required and subsequent experiments revealed that DPP-ddG, phosphatidyl-AZT and phosphatidyl 
analogs of other nucleosides were poorly absorbed after oral administration in mice. Early nucleoside 
analog antiviral agents like acyclovir (ACV) and ganciclovir (GCV) exhibited low oral bioavailability 
and we were interested in making analogs which were more active orally. Phospholipids are a part of 
normal dietary intake and specialized absorption pathways for lipids exist [13]. Humans ingest   Viruses 2010, 2  
 
 
2215
roughly 2 to 8 grams of phospholipid daily, which represents 1 to 10% of total daily fat intake, and 
phosphatidylcholine (lecithin) is the most common phospholipid in the diet. We took the approach to 
orally active lipid antivirals by basing the drug design on lysophosphatidylcholine (LPC), a partially 
degraded phospholipid formed in the small intestinal lumen from phosphatidyl-choline by the action of 
pancreatic phospholipase A2. Realizing that a substantial percentage of LPC is known to be absorbed 
intact [14,15], we replaced the acyl ester bond at the sn-1 glycerol position of LPC with an ether 
linkage to block hydrolysis of the acyl group by pancreatic lysophospholipase during absorption. 
Another advantage is that the alkyl ether analog is much more stable on storage than LPC which 
contains an acyl ester. Finally, the sn-2 hydroxyl of glycerol in LPC was replaced with a hydrogen 
atom in order to prevent reacylation by lysophosphatidylcholine acyltransferases which would result in 
the formation of diacylphosphatidyl nucleosides which we knew were poorly absorbed. We applied the 
design strategy to several nucleoside phosphate analogs using the hexadecyloxypropyl ester since this 
is the most common acyl substituent of LPC.  
3.1. Oral Activity of Acyclovir (ACV) and HDP-P-ACV in Woodchuck Hepatitis B and HSV-1 
Infections in vivo 
ACV-triphosphate is an effective inhibitor of hepatitis B virus (HBV) polymerase but ACV itself is 
not highly active in patients infected with HBV, indicating that ACV is not adequately phosphorylated 
in the liver to its triphosphate and does not show any anti-HBV activity [16,17]. We synthesized  
HDP-P-ACV (Figure 1) and found that the lipid prodrug has significantly enhanced activity against 
hepatitis B virus replication in 2.2.15 cells compared to ACV. Metabolic studies showed that the 
increased activity was due in part to much higher intracellular levels of ACV mono-, di-, and 
triphosphates  versus those levels found with exposure to acyclovir [18]. Using radiolabeled   
HDP-P-ACV, we found that the HDP-P-ACV was orally bioavailable and gave rise to excellent liver 
exposure in mice. Analysis of plasma showed that about half of the radioactive drug was circulating as 
HDP-P-ACV, the intact prodrug [18]. Oral HDP-P-ACV also proved to be effective in vivo against 
woodchuck hepatitis virus, providing a 2 log reduction in viral load while ACV at the maximal 
tolerated dose had no significant effect [19]. We also treated mice infected with HSV-1 with oral ACV 
or HDP-P-ACV. On a molar basis HDP-P-ACV, the lipid prodrug, was 2.4 times more active orally 
than ACV in preventing death from acute HSV-1 infection in mice [20].  
3.2. Oral Activity of HDP-P-GCV and HDP-P-PCV in HSV-1 Encephalitis 
Encouraged by these results with ACV, we synthesized and tested the HDP-phosphate esters of 
penciclovir (PCV) and ganciclovir (GCV), two agents known to have poor oral bioavailability   
(Figure 1). HDP-P-GCV was orally active against murine CMV and HSV-1 infections in mice, with 
antiviral activity equivalent to or greater than oral GCV [21]. With PCV, in vitro data showed that 
HDP-P-PCV was somewhat less potent than PCV against HSV-1. However, unmodified PCV showed 
little effect on mortality from intranasal HSV-1 infection in mice when given orally. In contrast, oral 
dosing of HDP-P-PCV (120 mg/kg, twice daily) showed a significant effect, reducing mortality in the 
infected mice from 87 to 40% [21]. Viruses 2010, 2  
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Figure 1. Structure of HDP-P esters of Acyclovir, Ganciclovir and Penciclovir. 
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4. Synthesis of HDP-CDV 
We next turned out attention to CDV, HPMPA, and the acyclic nucleoside phosphonates (ANPs). 
The ANPs can be regarded as close analogs of nucleoside monophosphates, except that they possess a 
metabolically stable phosphorus-carbon bond and lack a complete ribose or deoxyribose functionality. 
Unlike conventional nucleosides, ANPs do not require the often rate-limiting initial phosphorylation 
step for activation. As a result, ANPs like CDV and HPMPA are fully active against thymidine kinase 
or UL-97 mutant viruses which are resistant to acyclovir or ganciclovir. After conversion of ANPs to 
the active metabolite inside cells (ANP-diphosphate), the metabolites are generally retained inside cells 
for prolonged periods of time, which leads to more convenient dosing regimens [22]. However, ANPs 
have poor cellular permeation and oral bioavailability due to the charges on the phosphonic acid at 
physiologic pH levels. Another drawback involves their tendency to concentrate in the kidney 
proximal tubule, resulting in nephrotoxicity [22]. The next section describes the application of the 
alkoxyalkyl ester strategy to ANPs. 
Synthesis of HDP-Cyclic-CDV and HDP-CDV 
Building on early successes with HDP-P esters of acyclovir and ganciclovir, we synthesized the 
hexadecyloxypropyl and octadecyloxyethyl esters of CDV and cyclic CDV as shown in Figure 2 [23]. 
Briefly, CDV (1) was cyclized with dicyclohexylcarbodiimide to cyclic CDV (2) and esterified   
with 3-hexadecyloxy-1-propanol or 2-octadexyloxy-1-ethanol by the Mitsunobu reaction [24], yielding 
HDP-cyclic CDV (3) or ODE-cyclic CDV (4). The cyclic diesters were exposed to 0.5 N NaOH to 
open the ring, yielding HDP-CDV (5) or ODE-CDV (6). Alternative methods of synthesis of the 
alkoxyalkyl nucleoside phosphonates which are more suitable for scale up have been reported by 
Beadle and coworkers [25]. 
5. In vitro Antiviral Activity of HDP-CDV and ODE-CDV against Variola, Monkeypox, Cowpox 
and Vaccinia Viruses 
Table 1 shows the results of antiviral studies done in vitro with variola Bangladesh, monkeypox 
Zaire and cowpox Brighton in Vero 76 cells or MK2 cells in vitro [26]. The EC50 values of HDP-CDV 
against variola ranged from 0.04 to 0.1 M; octadecyloxyethyl-CDV (ODE-CDV) was somewhat 
more active at 0.01 to 0.03 M. The alkoxyalkyl esters were 25- to 910-fold more active than CDV. Viruses 2010, 2  
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Similar results were noted with monkeypox and cowpox viruses in vitro (Table 1). HDP-CDV and 
ODE-CDV were tested in vitro against vaccinia virus. The EC50 for CDV was 46.2 M compared  
with 0.8 M for HDP-CDV, an increase in antiviral activity of 58-fold. ODE-CDV was more active 
with an EC50 of 0.2 M, a 231 fold increase [27]. These results encouraged further evaluation of 
HDP-CDV and ODE-CDV as possible treatments for disease caused by vaccinia or variola infections.  
Figure 2. Synthesis of HDP-CDV and ODE-CDV. 
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Table 1. Antiviral Activity of HDP-CDV and ODE-CDV Against Variola, Monkeypox 
and Cowpox, in vitro. 
  Variola Bangladesh Monkeypox Zaire Cowpox Brighton 
Drug V76 MK2 V76 MK2 V76 MK2 
CDV  27.3 10.2  4.6 4.3  36.5  7.0 
HDP-CDV  0.10 0.04  0.07  0.13  0.10  0.008 
ODE-CDV  0.03 0.01  0.006 0.006  0.04  0.009 
Data are M EC50 values in Vero 76 cells (V76) or MK2 cells infected with Variola Bangladesh, 
Monkeypox Zaire or Cowpox Brighton. Adapted from Reference [26]. 
 
6. Mechanism of Action 
6.1. Mechanism of Increased Antiviral Activity of HDP-CDV 
The increase in antiviral activity noted with HDP-CDV compared to CDV itself was unusually large 
(100-fold or more). To investigate the reason for this, we next evaluated the cellular uptake and Viruses 2010, 2  
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metabolism of [2-
14C]-CDV and HDP-[2-
14C]-CDV in MRC-5 human lung fibroblasts, a common host 
cell for poxvirus study [28]. At four hours, the cellular radioactive drug content observed after 
exposure to 1 M CDV was only 1.2 versus 28 picomoles/well with 1.0 M HDP-CDV. At 
concentrations of 3 and 10 M, drug uptake of HDP-CDV was 77 and 245 picomoles/well, an increase 
of 11- to 23-fold versus CDV (Figure 3). At 3 and 10 M, the uptake of HDP-cCDV was 
approximately twice that of HDP-CDV and 32-fold greater than observed with cCDV (Figure 3). The 
mechanism of uptake has not been studied extensively, but it is believed that the HDP-CDV 
internalized after insertion into the plasma membrane bilayer outer leaflet as is typical for 
lysophospholipids. Transfer to the internal leaflet is probably spontaneous but may also be catalyzed 
by flippases. This process has not been studied in detail. In the cells phospholipase C or other 
phosphatases as yet unidentified, release CDV which is converted to the active metabolite by cellular 
enzymes. Conversion of HDP-CDV to CDV diphosphate (CDVpp), an analog of deoxycytidine 
triphosphate, was measured by HPLC. Cells exposed to CDV and HDP-CDV for 48 hours had 1.8  
and 184 picomoles of CDVpp, respectively; a difference of 100-fold [28]. Thus, it seems clear that 
increased antiviral activity of HDP-CDV is due to increased cellular uptake and conversion to CDVpp, 
the inhibitor of poxvirus DNA polymerase.  
Figure 3. Uptake of 
14C-labeled CDV, cyclic-CDV, HDP-cyclic-CDV and HDP-CDV in 
MRC-5 Human Lung Fibroblasts. Adapted from Reference 31. 
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6.2. Mechanism of Inhibition of Vaccinia DNA Polymerase by CDV Diphosphate 
The mechanism of inhibition of the vaccinia polymerase had not been studied previously. Using the 
purified vaccinia E9L DNA polymerase and different primer template pairs, Wendy Magee and David 
Evans found that CDV was incorporated into the growing DNA strand opposite template G’s but at a 
lower catalytic efficiency than dCTP [29]. CDV-terminated primers could be extended at the next 
addition step, but these CDV+1 reaction products are not good substrates for further synthesis. While 
CDV can be excised from the primer 3´ terminus by exonuclease of vaccinia virus polymerase, DNAs 
which have CDV as the penultimate 3´ residue were found to be completely resistant to exonuclease 
cleavage [29]. In addition, and perhaps more importantly, when CDV is present in the template strand, 
the vaccinia DNA polymerase is not able to bridge the CDV base, resulting in chain termination which 
prevents further rounds of replication; similar results were noted when HPMPA was incorporated into 
the template strand [30]. Interestingly, HPMPA, the adenine analog of HPMPC, inhibits exclusively by 
the latter mechanism. Thus, there are several important mechanisms by which CDV and HPMPA 
inhibit vaccinia virus replication.  
7. Early Studies of the Pharmacology and Toxicology of HDP-CDV in Mice 
Equimolar doses of 
14C-labeled CDV (5.6 mg/kg intraperitoneal) and HDP-CDV (10 mg/kg oral or 
intraperitoneal) were administered to mice [31]. After oral administration, HDP-CDV and metabolites 
in plasma reached their highest level, 2.34 μM, at three hours while intraperitoneal CDV showed a 
Cmax of 0.84 M at one hour. Comparison of the oral and parenteral areas under curve (AUC) 
indicated that the relative oral bioavailability of HDP-CDV was 88% [31]. The oral bioavailability of 
CDV in rats has been reported to be less than 3%. HDP-CDV persists in plasma following absorption 
in mice with a T½ of 14.9 hours and is converted to CDV and metabolites in the tissues [31].   
HDP-CDV is stable in plasma for several days at 37 °C and the plasma CDV noted after administration 
of HDP-CDV is a result of tissue metabolism.  
The tissue distribution of CDV, HDP-CDV and metabolites was determined using 
14C-labeled drugs 
and the Cmax and area under curve (AUC0-72hr) of drug and metabolites was calculated (Table 2). 
Several notable trends were apparent. The Cmax for intraperitoneal CDV in kidney was 180 
nanomoles/gm, 30-times that observed for oral HDP-CDV. When CDV is given intraperitoneally, most 
of the radioactive CDV appeared in the kidney and very little CDV was noted in brain, heart, liver, 
lung and spleen. In contrast, oral HDP-CDV delivered large amounts of the drug and metabolites to 
liver and and greater exposures in other tissues including brain. In kidney, HDP-CDV AUC was only 
19% of that observed with parenteral CDV, suggesting that the high kidney Cmax and AUC noted with 
parenteral CDV is responsible for its nephrotoxicity [31].  
Early oral toxicity studies with HDP-CDV showed that single doses of 100 mg/kg could be used 
safely [32]. However, significant weight loss and some mortality were noted at doses of 30 mg/kg/day 
for 7 to 14 days which was apparently due to gastrointestinal toxicity. No kidney or liver toxic effects 
were apparent (Hostetler, unpublished observations, 2002). We were able to use 1 to 10 mg/kg/day 
doses of HDP-CDV for up to 21 days in various animal models of viral disease.  
 Viruses 2010, 2  
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Table 2. Comparison of areas under curve with oral HDP-[2-
14C]-CDV and intraperitoneal  
[2-
14C]-CDV in mouse tissues. 
 AUC0-72hr AUC  Ratio 
Tissue CDV HDP-CDV H/C 
Brain 0.87 3.96  4.6 
Heart 3.46 14.26 4.1 
Liver 39.6  1366.0  34.5 
Lung 6.27 49.9  8.0 
Kidney 1093.0  203  0.19 
Spleen 9.92  53.2  5.4 
Data are nmol/gm.hrs after a single oral dose of 10 mg/kg HDP-[2-
14C]-CDV or a molar equivalent 
intraperitoneal dose of [2-
14C]-CDV (5.6 mg/kg). Ratio column abbreviation: H = HDP-CDV,   
C = CDV. Adapted from Reference [31]. 
 
8. Antiviral Activity in Poxvirus Disease 
8.1. Studies in Lethal Animal Models of Orthopoxvirus Disease 
In 2002, HDP-CDV was first tested in lethal cowpox virus infection in mice [33]. Full protection 
was noted when HDP-CDV was given orally at 5 mg/kg for five days and treatment was started two 
days post infection with 5 × 10
7 pfu of intranasal cowpox virus. Oral CDV was inactive, but   
a 100 mg/kg dose of intraperitoneal CDV provided full protection [33].  
In 2004, Mark Buller and coworkers [34] reported that HDP-CDV and ODE-CDV were active  
in vitro against ectromelia. When given orally to mice infected with ectromelia virus by small particle 
aerosol at 2.3 × 10
4 pfu/mouse, HDP-CDV and ODE-CDV were near fully protective by oral doses  
of 5 mg/kg and 10 mg/kg, respectively, when given four hours after infection and continued daily for five 
days [34]. Both HDP-CDV and ODE-CDV were effective in reducing mortality at 10 to 12.5 mg/kg for 
five days when given orally prior to or one, two or three days following intranasal infection with CPX 
or VV in BALB/c mice [35]. Mice treated 24 h after infection with the IHD strain of vaccinia virus 
with a single dose of 100, 50 or 25 mg/kg of HDP-CDV showed highly significant protection with zero 
to 20% mortality versus 100% mortality seen in untreated, infected mice [32]. HDP-CDV given orally 
also provides protection from infection with rabbitpox [36]. 
In 2008, Parker and coworkers [37] studied various infectious doses of ectromelia virus and found 
that the dose of HDP-CDV required for full protection from mortality varies with the dose of 
infectious virus. At high viral input doses (500–5,000 pfu/mouse), 8 mg/kg HDP-CDV for five days 
provided complete protection. With 50 pfu infectious doses of ectromelia virus, 2 mg/kg of HDP-CDV 
for five days provided 87% protection while low dose infections of less than 5 pfu of input virus 
required only 2 mg/kg of HDP-CDV for 5 days to achieve 100% protection [37].  
8.2. Results in Human Vaccinia Infection 
Recently a patient who was vaccinated for smallpox and later found to have leukemia developed a 
disseminated vaccinia virus infection. After being treated for 21 days with vaccinia immune globulin, Viruses 2010, 2  
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ST246 and imiquimod with little beneficial effect, the patient cleared the vaccinia infection rapidly 
after the addition of oral HDP-CDV (CMX001) to the treatment regimen [38]. Although this patient 
was cured by treatment with multiple agents, it seems quite clear from the clinical description that 
improvement coincided with the addition of oral therapy with CMX001.  
9. Current Status of Development of HDP-CDV (CMX001) 
CMX001 is under consideration as an agent for inclusion in the Strategic National Stockpile for 
emergency use in the event of a release of variola or for complications of smallpox vaccination. In 
addition to its antiviral activity against the orthopoxviruses, HDP-CDV has been shown to be active as 
an antiviral against all double stranded DNA (dsDNA) virus infections including human CMV [39]; 
HSV-1, HSV-2 and EBV [40], various strains of adenovirus [41], BK virus [42], orf [43], JC virus and 
human papilloma virus [44]. Currently, CMX001 has completed Phase I clinical trials in normal 
volunteers and Phase II trials are ongoing in CMV infections in stem cell transplant patients 
(NCT00942305) and BK virus infection in kidney transplant patients (NCT00793598). In addition, 
CMX001 has been used successfully in a number of emergency IND (E-IND) applications in patients 
having infections with CMV, HSV, adenovirus, BK virus and JC virus infections sponsored by 
Chimerix Inc., the licensee. Finally, an expanded access trial entitled “A Multicenter, Open-label 
Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses” is also 
open (NCT01143181).  
10. Conclusions 
HDP-CDV is a novel ether lipid antiviral which is orally active and lacks the nephrotoxicity of 
CDV itself. Increased oral bioavailability and increased cellular uptake, facilitated by the lipid portion 
of the molecule, is responsible for the improved activity profile. It is a highly effective agent against a 
variety of orthopoxvirus infections in animals including vaccinia, cowpox, rabbitpox and ectromelia. 
Its activity was recently demonstrated in disseminated vaccinia infection in man after HDP-CDV 
(CMX001) was added to a multiple drug regimen. In addition to the activity against orthopoxviruses, 
HDP-CDV (CMX001) is active against all dsDNA viruses including CMV, HSV-1, HSV-2, EBV, 
adenovirus, BK virus, orf, JC, and human papilloma viruses, and is in clinical development as a 
treatment for human infections with these viruses.  
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